Abstract
The human leucine-rich repeats and immunoglobulin like domains (LRIG) are evolutionary conserved family of single-pass transmembrane proteins. LRIG gene family includes three members, LRIG1 (formerly LIG1), LRIG2 and LRIG3, all of which are differentially expressed in human tissues and have long been proposed to be tumor suppressors. However, recently accumulated evidence on LRIG protein expression in human cancer appears to be inconsistent with this belief, as LRIG proteins have been found to be upregulated in certain tumors. Moreover, LRIG3 has been shown to act in an opposite manner to LRIG1 and LRIG1, in turn, has been shown to attenuate LRIG3 activity by its proteolytic degradation. These remarkable observations underline and reveal the previously unappreciated complexity of LRIG family dynamics. In the current review, the role of LRIG proteins in various human cancers is summarized and their differential regulation and expression is brought to light in order to understand how these proteins are involved in the genesis and progression of human cancers. Moreover, this is the first compilation that highlights the therapeutic potential of LRIG1 and suggests the same to be undertaken for LRIG2 and LRIG3. By virtue of their potential in prognosis of several cancer types, as well as their role as probable therapeutic proteins or in enhancing the receptiveness of the cancer cells to anti-tumor agents, it is strongly proposed that LRIG analysis should be undertaken and consequently be employed as a part of potential cancer treatment strategies.
Keywords: LRIGs, tumor suppressors, prognostic potential, human cancers, chemosensitivity, anti-tumor agents, therapeutic competence.
Current Cancer Drug Targets
Title:LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Volume: 17 Issue: 1
Author(s): Uzma Malik and Aneela Javed
Affiliation:
Keywords: LRIGs, tumor suppressors, prognostic potential, human cancers, chemosensitivity, anti-tumor agents, therapeutic competence.
Abstract: The human leucine-rich repeats and immunoglobulin like domains (LRIG) are evolutionary conserved family of single-pass transmembrane proteins. LRIG gene family includes three members, LRIG1 (formerly LIG1), LRIG2 and LRIG3, all of which are differentially expressed in human tissues and have long been proposed to be tumor suppressors. However, recently accumulated evidence on LRIG protein expression in human cancer appears to be inconsistent with this belief, as LRIG proteins have been found to be upregulated in certain tumors. Moreover, LRIG3 has been shown to act in an opposite manner to LRIG1 and LRIG1, in turn, has been shown to attenuate LRIG3 activity by its proteolytic degradation. These remarkable observations underline and reveal the previously unappreciated complexity of LRIG family dynamics. In the current review, the role of LRIG proteins in various human cancers is summarized and their differential regulation and expression is brought to light in order to understand how these proteins are involved in the genesis and progression of human cancers. Moreover, this is the first compilation that highlights the therapeutic potential of LRIG1 and suggests the same to be undertaken for LRIG2 and LRIG3. By virtue of their potential in prognosis of several cancer types, as well as their role as probable therapeutic proteins or in enhancing the receptiveness of the cancer cells to anti-tumor agents, it is strongly proposed that LRIG analysis should be undertaken and consequently be employed as a part of potential cancer treatment strategies.
Export Options
About this article
Cite this article as:
Malik Uzma and Javed Aneela, LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers, Current Cancer Drug Targets 2017; 17 (1) . https://dx.doi.org/10.2174/156800961701161202200445
DOI https://dx.doi.org/10.2174/156800961701161202200445 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Current Vascular Pharmacology Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Study on Adsorption and Sustained Release of Eucommia ulmoides Oliv. Leaf Extracts on Activated Carbon
Current Drug Delivery Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Glycosylation Pathways as Drug Targets for Cancer: Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Serine Protease Inhibitor Kazal Type 1 (SPINK1): Beyond the Trypsin Inhibitor
Current Enzyme Inhibition Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Aqueous Extracts of Selected Potentilla Species Modulate Biological Activity of Human Normal Colon Cells
Current Drug Targets Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein
Letters in Drug Design & Discovery In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Cancer Estimates in Brazil Reveal Progress for the Most Lethal Malignancies
Current Topics in Medicinal Chemistry Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy